Is pritelivir available in the US?

Is pritelivir available in the US?

Oral pritelivir is currently in a phase 2 clinical trial in the U.S., to assess efficacy and safety comparing pritelivir to i.v. foscarnet, a virostatic agent which is used mainly for the treatment of HSV resistant to other antiviral drugs.

Can I buy Pritelivir?

The development of Pritelivir for patients with high medical need is in clinical Phase 3 and Pritelivir is not yet available as a marketed product.

What is Pritelivir?

Pritelivir is a well-tolerated novel herpes simplex virus (HSV) helicase-primase inhibitor that reduced genital shedding and lesions.

What happens if herpes goes untreated?

What happens if herpes is not treated? Herpes can be painful, but it generally does not cause serious health problems like other STDs can. Without treatment, you might continue to have regular outbreaks, or they could only happen rarely. Some people naturally stop getting outbreaks after a while.

Is Famvir stronger than Valtrex?

valacyclovir vs. famciclovir, there is no winner. Valacyclovir, acyclovir and famciclovir are all safe, proven drugs that can be used effectively as treatments for HSV-1, HSV-2, shingles and other forms of the herpes virus.

What is the treatment for HSV-1?

AiCuris develops Pritelivir oral tablets for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections. A phase 2/3 trial in immunocompromised patients is ongoing.

What is AiCuris doing to improve access to Pritelivir?

AiCuris also supports expanded access requests for Pritelivir oral tablets for the treatment of eligible patients and collaborates with myTomorrows to facilitate early access to Pritelivir for acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

Can Pritelivir oral tablets help herpes patients with resistant HSV?

Early Access to Pritelivir oral tablets for immunocompromised patients with resistant HSV infections AiCuris develops Pritelivir oral tablets for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections. A phase 2/3 trial in immunocompromised patients is ongoing.

When will AiCuris present at the industry symposium 2021?

AiCuris will present at the Industry Symposium Friday 3rd Sep 2021, 2:10pm-3:10pm CET „PRITELIVIR – BEATING RESISTANT HSV INFECTIONS“ AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of herpes simplex virus infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial